Analyst Price Target is $0.00
▼ -100.00% Downside Potential
This price target is based on 0 analysts offering 12 month price targets for NovaBay Pharmaceuticals in the last 3 months. The average price target is $0.00, with a high forecast of $0.00 and a low forecast of $10,000,000.00. The average price target represents a -100.00% upside from the last price of $0.69.
Current Consensus is
The current consensus among 0 investment analysts is to n/a stock in NovaBay Pharmaceuticals. This rating has held steady since September 2022, when it changed from a Buy consensus rating.
NovaBay Pharmaceuticals, Inc. engages in the development and sales of scientifically-created and clinically-proven eyecare and skincare. Its products include Avenova, NeutroPhase, CelleRx, and DERMAdoctor. The company was founded on January 19, 2000 and is headquartered in Emeryville, CA.